|
|
| Name |
Baylin, Stephen B. |
| Location
|
Johns Hopkins University School of Medicine |
| Primary Field
|
Medical Genetics, Hematology and Oncology |
 Election Citation
|
|
Baylin first recognized and mechanistically confirmed that abnormal promoter DNA methylation could substitute for mutations in mediating loss-of-function of cancer tumor suppressor genes. This opened the field of cancer epigenetics and led to insights for establishing epigenetic therapies and biomarker strategies to improve cancer management. |
|
Research Interests
|
|
Dr. Baylin recognized a process of cancer specific, abnormal gene promoter, CpG island DNA methylation associated with epigenetically mediated gene silencing and defined this as an alternative to mutations for producing loss of function for tumor suppressor genes. Baylin was born in Durham, N.C. where he grew up and attended Duke University to obtain his B.A and M.D. degrees. He did his internship in Internal Medicine at Duke and completed his residency for this at Johns Hopkins. He did research training at the NIH in Bethesda, MD as a Staff Associate and Research Investigator from 1969-1971 and did a post-doctoral fellowship in Endocrinology and Physiology at Johns Hopkins from 1972-73. He joined the faculty in the Johns Hopkins Medical Institutions in 1974 and rose to full Professor in the departments of Oncology and Medicine and the Sidney Kimmel Comprehensive Cancer Center in 1986 where he has remained until the present. He holds the Ludwig Professor Chair in Oncology, served as Deputy Director of the Cancer Center from 1992 until 2015 and Associate Director of Research from 2007 through 2015. He is currently co-director of the Cancer Biology Program in the Cancer Center. Dr. Baylin is also a Professor at the Van Andel Research Institute since 2015 and co-Director of a Stand up to Cancer Team for epigenetic therapy. He was elected to the National Academy of Science in 2017. |
|
|
|